EURASIAN JOURNAL OF EMERGENCY MEDICINE

Acute coronary syndrome (ACS) including unstable angina (UA), non-ST-elevation myocardial infarction (NSTEMI) and ST-elevation myocardial infarction (STEMI) continue to be the main reason of mortality and morbidity all around the world despite the advancing medical technologies, many factors revealed in the ethiopathogenesis and developments in coronary artery disease (CAD) treatment. Many studies on atherosclerotic disease that has increasing prevalence are conducted and new results are obtained (1). Cardiac troponin (cTn) is quite sensitive and is a specific indicator of myocardial damage. Increased levels of cTn have importance in ACS concerning prognosis and course of the treatment. Therefore, measurements of cTn levels are often used for differential diagnosis in ACS in the emergency department (ED) and intensive care units (2-5). However, it is impossible to detect the patients with ACS who have high risk via serum troponins, because myocardial necrosis is not seen in many of these patients. Therefore, new cardiac biomarkers, which will help rapid and absolute diagnosis, are required in order for risk evaluation in the patients with ACS, before the traditional markers, which indicate myocardial cell damage and in case where these markers do not Aim: The study aimed to investigate the prognostic value of serum procalcitonin (PCT) levels in patients with acute coronary syndrome (ACS).